Navigation Links
ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008
Date:1/4/2008

DENVER, Jan. 4 /PRNewswire/ -- ARCA Discovery Inc., a privately held biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced Richard B. Brewer, President and Chief Executive Officer, will present at the 26th Annual JPMorgan Healthcare Conference on Tuesday, January 8 at 2:00 PM PT.

The JPMorgan Healthcare Conference will be held January 7-10, 2008 at the Westin St. Francis in San Francisco, California.

About ARCA Discovery, Inc.

ARCA Discovery, Inc. is a privately-held biopharmaceutical company based in Denver, Colorado developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company's first product is bucindolol, a next generation beta-blocker for chronic heart failure, which promises to be the first personalized, genetically-targeted cardiovascular therapy. ARCA plans to file for FDA approval of bucindolol in 2008, and to leverage its platform to develop other pharmacogenetic therapies for cardiovascular diseases. The Company recently closed a Series B round of $18 million, led by new investors Skyline Ventures and InterWest Partners. ARCA completed a $15 million Series A round in 2006 led by Atlas Venture and Boulder Ventures, which also participated in the Series B round.

About Bucindolol

ARCA has exclusive worldwide rights to bucindolol, a next generation beta-blocker for chronic heart failure. ARCA's cardiovascular platform combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development, in a unique approach that enables the efficient identification of pharmacogenetic targets. Applying this approach to bucindolol, ARCA has identified pathways affecting bucindolol response that are modulated by common genetic variations. This discovery is supported by substantial Phase 3 data, and will allow a physician to determine whether bucindolol is the right therapy for a patient with a simple genetic test. ARCA has partnered with Laboratory Corporation of America to develop the bucindolol genetic test. Prescribed by using this test, bucindolol could have significant advantages for many chronic heart failure patients. With experience in commercializing cardiovascular products, ARCA plans to market bucindolol in the U.S. through its own sales force.


'/>"/>
SOURCE ARCA Discovery Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
2. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
3. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
4. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
5. AutoGenomics Invited to Present at the JPMorgan Healthcare Conference
6. Thermage, Inc. to Present at the 10th Annual Needham & Company Growth Conference
7. Advanced Life Sciences to Present at Biodefense Session of 26th Annual JPMorgan Healthcare Conference
8. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
9. Xoft to Present at the 26th Annual JPMorgan Healthcare Conference
10. Danaher to Present at J.P. Morgan Healthcare Conference
11. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):